Clinical Stage
Program 1
Unmet Need
- Prevention of Myopia progression in children aged 7 to 17
Status
- 12 years named patient use trial completed in Denmark
- First therapeutic product globally for myopia control
Clinical Phase & IP
- Phase 3 Clinical Trial in 2024
- 20 Years IP
Program 2
Unmet Need
- Reduce risk of ARDS Phase 1 progressing to Phase 2 in Covid-19 patients
- Improve patient post Covid-19 recovery
Status
- Investigator clinical trial in 15 patients in October 2020 completed successfully
Clinical Phase & IP
- Phase 3 double-blind 180 clinical study completed
- Patent filed September 2020
Program 3
Unmet Need
- Prevention of preterm birth in pregnant women
Status
- Novel dosage form with 500% improved bio-availability
- First product globally
Clinical Phase & IP
- Patent filed September 2019
- Phase 3 Clinical Trial 2024
